iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 698 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Reflections from the World Cancer Congress November 30, 2022 Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer June 24, 2020 Food for thought: new insights into how chemotherapy causes cachexia June 15, 2022 Load more HOT NEWS Patients less likely to rate cancer care as ‘very good’ during... Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone... Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... Maintenance Therapy with CC-486 Extends Survival of Adults with AML
